➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Johnson and Johnson
AstraZeneca
McKesson
Boehringer Ingelheim

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EXPAREL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Exparel

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01349140 EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks Completed Pacira Pharmaceuticals, Inc Phase 1/Phase 2 2012-02-01 EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to determine the effect on thigh muscle strength and skin sensitivity of various doses of EXPAREL when placed next to the nerve that goes to the thigh.
New Formulation NCT01349140 EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks Completed University of California, San Diego Phase 1/Phase 2 2012-02-01 EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to determine the effect on thigh muscle strength and skin sensitivity of various doses of EXPAREL when placed next to the nerve that goes to the thigh.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Exparel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00485433 Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair Completed Pacira Pharmaceuticals, Inc Phase 2 2007-06-01 The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl.
NCT00485693 Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty Completed Pacira Pharmaceuticals, Inc Phase 2 2007-06-01 Dose-ranging study for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty
NCT00529126 Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy Completed Pacira Pharmaceuticals, Inc Phase 2 2007-09-01 Phase 2 study to evaluate three dose levels of SKY0402 compared with 75 mg of bupivacaine HCl.
NCT00813111 Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation Terminated Pacira Pharmaceuticals, Inc Phase 3 2008-11-01 The purpose of this study is to provide a more effective postoperative method of pain control for patients undergoing cosmetic sub-muscular breast augmentation. Appropriate postoperative pain management contributes to faster patient mobilization, shortened hospital stays, and reduced healthcare costs.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exparel

Condition Name

Condition Name for Exparel
Intervention Trials
Pain, Postoperative 28
Pain 25
Postoperative Pain 21
Opioid Use 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Exparel
Intervention Trials
Pain, Postoperative 70
Osteoarthritis 16
Osteoarthritis, Knee 9
Fractures, Bone 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Exparel

Trials by Country

Trials by Country for Exparel
Location Trials
United States 242
Denmark 3
Belgium 3
Georgia 1
Poland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Exparel
Location Trials
Ohio 26
Texas 24
New York 23
Florida 17
California 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Exparel

Clinical Trial Phase

Clinical Trial Phase for Exparel
Clinical Trial Phase Trials
Phase 4 124
Phase 3 22
Phase 2/Phase 3 5
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Exparel
Clinical Trial Phase Trials
Recruiting 65
Not yet recruiting 60
Completed 44
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Exparel

Sponsor Name

Sponsor Name for Exparel
Sponsor Trials
Pacira Pharmaceuticals, Inc 57
Mayo Clinic 8
The Cleveland Clinic 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Exparel
Sponsor Trials
Other 183
Industry 61
U.S. Fed 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
AstraZeneca
Harvard Business School
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.